Bioxcel therapeutics reports q1 loss per share of $0.79

Bioxcel therapeutics reports first quarter 2020 financial results and provides business update.enrollment of pivotal serenity trials is progressing well, with topline data expected in mid-2020.co is assessing data for dose escalation in tranquility study and is on track to report results in mid-2020.qtrly loss per share $0.79.q1 earnings per share view $-0.60 -- refinitiv ibes data.
BTAI Ratings Summary
BTAI Quant Ranking